^
BIOMARKER:

PD-L1 negative

i
Other names: PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule
Entrez ID:
Related biomarkers:
PD-L1 negative
SCCHN
methotrexate
Sensitive: A2 - Guideline
PD-L1 negative
SCCHN
TPeX
Sensitive: A2 - Guideline
PD-L1 negative
SCCHN
pembrolizumab
Sensitive: A2 - Guideline
PD-L1 negative
SCCHN
cetuximab
Sensitive: A2 - Guideline
PD-L1 negative
SCCHN
5-fluorouracil
Sensitive: A2 - Guideline
PD-L1 negative
Melanoma
pembrolizumab
Sensitive: B - Late Trials
PD-L1 negative
NSCLC
pembrolizumab
Sensitive: C2 – Inclusion Criteria
PD-L1 negative
NSCLC
avelumab + VX15
Sensitive: C3 – Early Trials
PD-L1 negative
NSCLC
nivolumab
Resistant: C3 – Early Trials
PD-L1 negative
Urothelial Cancer
nivolumab + IPI-549
Sensitive: C3 – Early Trials
PD-L1 negative
Vulvar Cancer
pembrolizumab
Sensitive: C3 – Early Trials
PD-L1 negative
Melanoma
pembrolizumab + ipilimumab
Sensitive: C3 – Early Trials
PD-L1 negative
Cervical Cancer
AGEN2034
Sensitive: C3 – Early Trials
PD-L1 negative
SCCHN
pembrolizumab + SNS-301
Sensitive: C4 – Case Studies
PD-L1 negative
Merkel Cell Carcinoma
avelumab
Sensitive: C4 – Case Studies
PD-L1 negative
Small Cell Lung Cancer
pembrolizumab
Sensitive: C4 – Case Studies
PD-L1 negative
Colon Cancer
KD033
Sensitive: D – Preclinical